Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) disclosed that it has received the FDA authorization for LUPKYNIS™ (voclosporin). To treat Lupus Nephritis, LUPKYNIS is the first oral therapy that has got the endorsement of the FDA to treat adult sufferers with active lupus nephritis.

Lupus Nephritis is the condition in which patients experienced kidney failure which automatically increases the chances of Kidney failure, cardiac issues, and even cause the death of an affected person. LN is the most severe and most widespread problem of the autoimmune disease systemic lupus erythematosus (SLE). LUPKYNIS is currently available to patients in the US.

In the trial of LN, the treatment of patients with LUPKYNIS in conjunction with standard-of-care (SoC). The sufferers have undergone a positive response. This treatment has reduced the urine protein creatinine ratio (UPCR) twice as quickly as patients being treated with typical SoC. Protein levels in the kidney can be measured using UPCR.

The approval which the firm has got for LUPKYNIS is the greatest achievement not for the firm but for the patients of LN as well. The firm is excited to bring new treatment for the people who are suffering from the deadly condition for decades. The authorization of the FDA for LUPKYNIS enables the firm to treat the patients with more safety.

Furthermore, apart from this achievement, the firm has also introduced the Aurinia Alliance which is a backing program including devoted nurse managers who offer educational resources and aid in directing insurance and Aurinia medication costs during each patient’s LUPKYNIS treatment journey.

Patients with LN are desperately waiting for the authorized treatment and this authorization of the FDA for LUPKYNIS is a ray of hope for the sufferers. The FDA has granted the authorization under priority review and earlier Fast Track Designation has been awarded in 2016.